Coleman Mark's Form 4 filing
Axsome Therapeutics, Inc.AXSM · filed Feb 27, 2026
- Accession no.
- 0001193125-26-083587
- Filed
- Feb 27, 2026
- Trade date
- Feb 26, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $4.03M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Coleman MarkCIK 0001658379 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Common Stock | SSaleDisposed | −25,000 | $161.11F3 | −$4,027,750 | 47,140 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.33 and $162.26.
Referenced by the price of 1 transaction in Table I.